A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants | NCT07727538

NCT07727538

Overview

NCT ID: NCT07727538
Lead Sponsor: Ionis Pharmaceuticals, Inc.INDUSTRY
Official Title: An Open-Label Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Pediatric Patients With Familial Chylomicronemia Syndrome (FCS)
Brief Summary: The primary purpose of the study is to evaluate the efficacy of olezarsen administered by subcutaneous injection to pediatric participants with FCS.
Conditions: Familial Chylomicronemia Syndrome
Interventions: Olezarsen

Status and Timeline

Status: Recruiting
Last Update Posted: Jul 29, 2026Actual
Start Date: Jul 2026Estimated
Primary Completion Date: Aug 2030Estimated
Completion Date

Participation Criteria

Ages Eligible for Study: Child (0-17)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Key Inclusion Criteria:

Parental or legally authorized representative consent must be obtained, and the participants must provide age-appropriate or cognition-appropriate assent, as determined by the Investigator. The parent or legal guardian must be able to understand and comply with the study visit schedule and all other study procedures.

Must be able to comply with all study procedures.

Age 12 to less than 18 years at the time of informed consent/assent (Cohort 1); age 2 to less than 12 years at time of informed consent/assent (Cohort 2).

Willing to fast for at least 10 hours before visits requiring fasted blood sampling.

A diagnosis of Familial Chylomicronemia Syndrome (type 1 Hyperlipoproteinemia) by documentation of confirmed homozygote, compound heterozygote or double heterozygote for loss-of-function mutations in type 1-causing genes.

Fasting TGs ≥880 mg/dL at screening. If fasting TG is < 880 mg/dL, up to two additional tests may be performed during the screening period with any single test used to qualify.

Key Exclusion Criteria:

Diabetes mellitus with any of the following:

Newly diagnosed within 12 weeks prior to screening or during the screening period.

Hemoglobin A1c (HbA1c) ≥9.5% at screening.

Change in basal insulin regimen >20% within 3 months prior to screening or during the screening period.

For participants with type 1 diabetes: episode of diabetic ketoacidosis, or ≥3 episodes of severe hypoglycemia within 6 months prior to screening or during the screening period.

History of bleeding, diathesis, or coagulopathy.

Major surgery within 3 months of screening.

Plasma apheresis within 4 weeks prior to screening or planned during the study.

Treatment with another investigational drug, biological agent, or device within one month of screening, or 5 half-lives of investigational agent, whichever is longer.

Active pancreatitis within 4 weeks prior to screening or during the screening period.

Malignancy diagnosed or treated within 5 years prior to screening or during the screening period.

Note: Other protocol-specified inclusion/exclusion criteria may apply.

Study Plan

Study Type: Interventional
Phase: Phase 3
Enrollment: 12Estimated
Primary Purpose: Treatment
Allocation: N/A
Interventional Model: Parallel Assignment
Masking: None (Open Label)

Contacts and Locations

Central Contacts: Ionis Pharmaceuticals, Inc.Contact
IonisOlezarsenPediatric@clinicaltrialmedia.com

Similar Studies

Participant Group/Arms

Cohort 1Experimental

Participants aged 12 to \<18 years will receive multiple doses of olezarsen, at a dose level that depends on body weight, once every month by subcutaneous injection for up to 1 year. All participants may continue to the optional 1-year long-term extension period with the last dose received being after 2 years of treatment.

Drug: Olezarsen

Cohort 2Experimental

Participants aged 2 to \<12 years will receive multiple doses of olezarsen, at a dose level based on information obtained from Cohort 1, once every month by subcutaneous injection for up to 1 year. All participants may continue to the optional 1-year long-term extension period with the last dose received being after 2 years of treatment.

Drug: Olezarsen